Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2014
09/16/2014CA2674530C Spirochromanon derivatives
09/16/2014CA2658001C Novel glucokinase activators and methods of using same
09/16/2014CA2650970C P38 map kinase inhibitors
09/16/2014CA2650342C Chromium complexes
09/16/2014CA2649845C Terphenyl derivatives for treatment of alzheimer' s disease
09/16/2014CA2633040C Composition of inverse emulsion type comprising ivermectin, and uses thereof in cosmetics and dermatology
09/16/2014CA2611831C A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
09/16/2014CA2604895C (1h-indol-7-yl)-( (pyrimidin-2-ylamino) methanone derivatives and related compounds as igf-r1 inhibitors for the treatment of cancer
09/16/2014CA2596235C Spiroketal derivatives and use thereof as diabetic medicine
09/16/2014CA2574303C Modafinil oral lyophilizate
09/16/2014CA2574220C Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
09/16/2014CA2570887C Tumor treatment
09/16/2014CA2569856C Prebiotic preparation
09/16/2014CA2504532C Botulinum neurotoxin b receptors and use thereof
09/16/2014CA2484420C Antibodies specific for human cd22 and their therapeutic and diagnostic uses
09/16/2014CA2454644C Cannabinoid liquid formulations for mucosal administration
09/16/2014CA2445796C Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
09/16/2014CA2408791C Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
09/15/2014CA2846402A1 Methods and device for treating opioid addiction
09/15/2014CA2819448A1 Use of lxr antagonists for treatment of side effects of elevated glucocorticoid levels
09/15/2014CA2809686A1 Use of minocycline for therapeutic treatment of acute spinal cord injuries
09/12/2014WO2014138712A1 Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
09/12/2014WO2014138708A1 Methods and compositions for transdermal delivery of caffeine in the forms of solution or suspension
09/12/2014WO2014138692A1 Mixed lineage kinase inhibitors and method of treatments
09/12/2014WO2014138628A1 Bioadhesive hydrogel
09/12/2014WO2014138616A2 Pyrazole compounds and methods of use thereof
09/12/2014WO2014138589A2 Copper (i) complexes with glycine, pyruvate, and succinate
09/12/2014WO2014138556A1 Kits and methods for the treatment of cancer using gliadin peptides
09/12/2014WO2014138508A1 Novel transcription factor modulators
09/12/2014WO2014138507A1 Treatment of cervical cancer and/or ovarian cancer using a transcription factor modulator
09/12/2014WO2014138505A1 Treatment of cancer and other conditions using a transcription factor modulator
09/12/2014WO2014138501A2 Compositions and methods for the treatment of skin diseases
09/12/2014WO2014138484A1 Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
09/12/2014WO2014138460A1 2-aminopyridine-based selective neuronal nitric oxide synthase inhibitors
09/12/2014WO2014138452A1 Kinase inhibitors
09/12/2014WO2014138391A1 Targeting glutamine metabolism in brain tumors
09/12/2014WO2014138378A1 NOVEL MIXED μ AGONIST/ δ ANTAGONIST OPIOID ANALGESICS WITH REDUCED TOLERANCE LIABILITIES AND USES THEREOF
09/12/2014WO2014138374A1 Oral combination therapy for treating hcv infection in specific patient sub-population
09/12/2014WO2014138368A1 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
09/12/2014WO2014138367A1 Inhibition of tumor growth with aggregates of small molecules
09/12/2014WO2014138357A1 Novel tashinone drugs for alzheimer disease
09/12/2014WO2014138338A1 Combinatorial compositions and methods for treatment of melanoma
09/12/2014WO2014138302A1 Quinazolinone antibiotics
09/12/2014WO2014138298A1 Treatment of demyelinating disorders
09/12/2014WO2014138279A1 Compounds for treatment of cancer
09/12/2014WO2014138241A1 Pharmaceuticals for oral delivery
09/12/2014WO2014138239A1 Compounds for the treatment of hepatitis c
09/12/2014WO2014138212A1 CaMKII INHIBITORS AND USES THEREOF
09/12/2014WO2014138199A1 Pyrimidine compounds for the treatment of hepatitis c
09/12/2014WO2014138162A1 Preparations for the treatment of sleep-related respiratory disorders
09/12/2014WO2014138088A1 Bmp inhibitors and methods of use thereof
09/12/2014WO2014138085A1 Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular drug delivery
09/12/2014WO2014138075A1 Phosphonic acid compounds as sphingosine-1-phosphate receptor modulators
09/12/2014WO2014138046A1 Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
09/12/2014WO2014138037A1 Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
09/12/2014WO2014138018A1 Preservative free bimatoprost and timolol solutions
09/12/2014WO2014137930A1 Thiophosphate nucleosides for the treatment of hcv
09/12/2014WO2014137929A1 Methods for treating hepatitis c virus
09/12/2014WO2014137926A1 3'-deoxy nucleosides for the treatment of hcv
09/12/2014WO2014137883A1 2-pyridyloxy-4-ether orexin receptor antagonists
09/12/2014WO2014137877A1 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
09/12/2014WO2014137848A1 PENTACYCLIC PYRIDOINDOLOBENZ[b,d]AZEPINE DERIVATIVES AND USES THEREOF
09/12/2014WO2014137811A1 Compositions and methods for repelling blood-sucking and biting insects, ticks and mites
09/12/2014WO2014137799A1 Solid compositions comprising a glucokinase activator and methods of making and using the same
09/12/2014WO2014137741A1 Hdac inhibitors for treating traumatic brain injury
09/12/2014WO2014137728A1 Compounds inhibiting leucine-rich repeat kinase enzyme activity
09/12/2014WO2014137725A1 Compounds inhibiting leucine-rich repeat kinase enzyme activity
09/12/2014WO2014137723A1 Compounds inhibiting leucine-rich repeat kinase enzyme activity
09/12/2014WO2014137719A1 Compounds inhibiting leucine-rich repeat kinase enzyme activity
09/12/2014WO2014137576A1 Isohexide monotriflates and process for synthesis thereof
09/12/2014WO2014137395A1 Salicylic acid gel
09/12/2014WO2014137385A1 Intrathecal hydromorphone solutions having improved stability
09/12/2014WO2014137301A1 Hydrazones and thiazolidinones derived from diflunisal
09/12/2014WO2014137234A1 Method for fasting-diet therapy
09/12/2014WO2014137231A2 Totarol extract formulations and uses thereof
09/12/2014WO2014137090A1 Formulation for prevention or treatment of diabetes
09/12/2014WO2014136944A1 Aqueous liquid composition including high concentration of l-histidine
09/12/2014WO2014136808A1 Cell-death inhibitor, and production method therefor
09/12/2014WO2014136807A1 Cell-death inhibitor, and novel compound
09/12/2014WO2014136786A1 Novel compound
09/12/2014WO2014136730A1 Oxidation reaction with excellent conversion rate
09/12/2014WO2014136717A1 Transdermally absorbable pharmaceutical composition
09/12/2014WO2014136681A1 Water-soluble flavonoid composition; drink, food, pharmaceutical product and cosmetic product, each of which contains same; and method for producing water-soluble flavonoid composition
09/12/2014WO2014136672A1 Ectoparasite control agent
09/12/2014WO2014136494A1 Enteric-coated fine particle and drug composition
09/12/2014WO2014136453A1 C12orf48 PEPTIDES AND VACCINES CONTAINING THE SAME
09/12/2014WO2014136305A1 Morphinan derivative
09/12/2014WO2014136282A1 Crystalline form having specific crystal habit and pharmaceutical composition|containing this crystalline form as active ingredient
09/12/2014WO2014136161A1 Osteopontin production inhibitor comprising dictyopyrone derivative or dihydrodictyopyrone derivative as active ingredient
09/12/2014WO2014136126A2 A process for preparing erlotinib hydrochloride form a
09/12/2014WO2014136116A1 Lipid conjugates in the treatment of bronchitis
09/12/2014WO2014136100A1 Modified poly(beta-amino ester)s for drug delivery
09/12/2014WO2014136086A1 Lipids and lipid compositions for the delivery of active agents
09/12/2014WO2014136079A1 Oral formulations of deferasirox
09/12/2014WO2014136075A1 H3 antagonists containing phenoxypiperidine core structure
09/12/2014WO2014136059A2 Prodrugs of multifunctional nitroxide derivatives and uses thereof
09/12/2014WO2014136048A1 Formulations of organic compounds
09/12/2014WO2014136036A1 Nutritional and medicinal oral composition for veterinary use
09/12/2014WO2014136035A1 Nutritional and medicinal oral composition for veterinary use
09/12/2014WO2014135956A1 Composition for use in the treatment of polycystic ovary syndrome
1 ... 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 ... 7860